HEALTHSTAT NEWS
FDA advisory panel narrowly rejects compounding of one peptide, back another
An FDA advisory panel recommended allowing compounding pharmacies to manufacture the peptide epitalon but narrowly voted against emideltide. The decision brings health secretary Robert F. Kennedy, Jr. closer to expanding access to unapproved peptides, which have gained popularity through social media influencers.
Mentioned
Related Signal
Adjacent reporting
- FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers
- FDA panel overrules its own scientists to ease access to unproven peptide injections
- FDA panel votes to add peptides to permitted list despite opposition from agency scientists
- FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists